Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | GattaCo and iAssay Join Forces in COVID-19 TestingBy: iAssay, Inc. "Helping to alleviate the COVID-19 testing bottleneck with improved test accuracy, eliminating the need for centrifugation of blood samples and reducing clinical lab restrictions will improve patient care and at the same time, provide public health agencies and other vested parties relevant data to support informed decision making and improved management of the COVID-19 crisis," said Dr. Michael McNeely, President and CEO of GattaCo. Combining Power GattaCo developed and patented rapid and automatic plasma separation tools, called the A-PON™ and pediatric-focused mini-PON™ Kits. The PON Kits (PON referring to plasma at the point of need) separate antibody-rich plasma from whole blood collected from a finger-stick without the need for a centrifuge or venous blood-draw. The plasma generated by the PON Kits can transform a normally Yes or No antibody test to a semi-quantitative test and enable more sensitive quantitative detection by the iAssay CyberReader™ iAssay's CyberReader™ An Elegant and Complimentary Solution When used as directed, PON derived plasma can be obtained in under three minutes, in any setting, including at a doctor's office, at home, at screening centers, or anywhere finger-stick blood can be collected. The A-PON and mini-PON Kits require no power, support equipment or skill on the part of the user, eliminating the need for the phlebotomist, lab tech and centrifuge infrastructure that is otherwise required to obtain plasma. The battery-powered iAssay CyberReader™ "It's a natural fit for both companies," said Lonnie Adelman, CEO & Founder at iAssay. "iAssay provides a sensitive and accurate Reader device and Cloud connectivity, and GattaCo provides the microfluidics that optimize the strip chemical reactions. Together, we are working on improving the full system performance by using our combined strengths in engineering and biotechnological medical device design," Adelman added. For more information on iAssay or GattaCo: Mahmoud Zubaidi Chief Science Officer Mahmoud.Zubaidi@ www.gattaco.com End
Account Email Address Disclaimer Report Abuse
|